Jean-Marie Eveillard recently increased his stakes in biotech company Arqule Inc (ARQL, Financial), according to GuruFocus Real Time Picks.
Arqule Inc researches and develops cancer therapeutics using its ArQule Kinase Inhibitor Platform (AKIPTM) to design and develop drugs. Its products and projects range from drug discovery to advanced clinical testing.
According to the company's most recent press release, it will be teaming with Beryllium Discovery Corp under a collaborative research and development agreement to "idenfity and unlock the therapuetic potential of small molecule compounds by combining Arqule's chemistry and drug development expertise with Beryllium's discovery platforms."
Eveillard purchased 3,264,283 shares of ARQL at an average price of $2.05 a share. The stock is currently trading at $2.03 a share.
Revenue per share for the trailing 12 months as of December 2014 was $0.18, and its growth rate for the year was -30.80%. One warning sign investors should be aware of is revenue has been declining over the past five years.
